Amedisys (AMED) PT Raised to $130.00 at SunTrust Banks

Amedisys (NASDAQ:AMED) had its price target upped by stock analysts at SunTrust Banks to $130.00 in a report issued on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the health services provider’s stock. SunTrust Banks’ target price suggests a potential upside of 18.96% from the stock’s previous close.

Several other research analysts also recently commented on the company. Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 3rd. Bank of America set a $139.00 price objective on Amedisys and gave the stock a “buy” rating in a report on Tuesday, September 18th. Cantor Fitzgerald initiated coverage on Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective on the stock. Canaccord Genuity initiated coverage on Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price on the stock. Finally, ValuEngine raised Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Amedisys currently has a consensus rating of “Buy” and a consensus price target of $95.38.

AMED opened at $109.28 on Thursday. The stock has a market capitalization of $3.98 billion, a PE ratio of 49.45, a P/E/G ratio of 1.89 and a beta of 1.00. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30. Amedisys has a 12 month low of $45.60 and a 12 month high of $127.38.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, July 31st. The health services provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. The firm had revenue of $411.60 million for the quarter, compared to the consensus estimate of $403.62 million. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. During the same quarter in the previous year, the business earned $0.62 earnings per share. On average, analysts predict that Amedisys will post 3.41 earnings per share for the current year.

In related news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total value of $48,440.58. Following the sale, the insider now directly owns 11,818 shares of the company’s stock, valued at $1,438,368.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new stake in shares of Amedisys in the second quarter worth about $149,000. SG Americas Securities LLC bought a new stake in shares of Amedisys in the first quarter worth about $123,000. Moneta Group Investment Advisors LLC bought a new stake in shares of Amedisys in the second quarter worth about $181,000. Cubist Systematic Strategies LLC boosted its position in Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after acquiring an additional 2,172 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new stake in Amedisys during the 1st quarter valued at approximately $151,000. 93.31% of the stock is currently owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Recommended Story: Return on Equity (ROE)

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with's FREE daily email newsletter.

Leave a Reply